3 days ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis StudyZacks
Alnylam shares interim phase I amyloidosis study data on nucresiran, showing rapid TTR reduction sustained for six months after a single dose.
XAlnylam shares interim phase I amyloidosis study data on nucresiran, showing rapid TTR reduction sustained for six months after a single dose.
X